Overview

* ADMA Q3 revenue grows 12% yr/yr, beating analyst expectations

* Adjusted net income for Q3 beats analyst estimates

* Adjusted EBITDA for Q3 misses analyst expectations

Outlook

* ADMA raises FY 2025 revenue guidance to at least $510 mln

* Company raises FY 2026 revenue guidance to at least $630 mln

* ADMA expects margin expansion from yield-enhanced batches starting Q4 2025

Result Drivers

* ASCENIV DEMAND - Record utilization and anticipated payer coverage expansion expected to support sustained revenue growth

* YIELD-ENHANCED PRODUCTION - FDA lot release of yield-enhanced batches expected to drive margin expansion starting Q4 2025

* CAPITAL STRUCTURE - Ongoing share repurchases and strengthened capital structure support long-term stockholder value

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $134.20 $131.20

Revenue mln mln (3

Analysts

)

Q3 Beat $38.90 $38.30

Adjusted mln mln (3

Net Analysts

Income )

Q3 Net $36.40

Income mln

Q3 Miss $58.70 $61.50

Adjusted mln mln (2

EBITDA Analysts

)

Q3 Gross $75.60

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for ADMA Biologics Inc ( ADMA ) is $30.00, about 51.2% above its November 4 closing price of $14.63

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)